Travere Therapeutics
Travere Therapeutics, Inc. is a biopharmaceutical company dedicated to the identification, development, and commercialization of therapies for rare diseases, particularly in the fields of nephrology, hepatology, and metabolism. The company markets several products, including Chenodal for the treatment of gallbladder stones, Cholbam for bile acid synthesis disorders, and Thiola for cystinuria. Its key pipeline candidate, Sparsentan, is in Phase III clinical trials for focal segmental glomerulosclerosis and immunoglobulin A nephropathy, both serious kidney conditions. Additionally, Travere sponsors no-cost genetic testing to aid in the diagnosis of cholestasis in children and collaborates with patient advocacy organizations to support the needs of patients and their families. Founded in 2011 and headquartered in San Diego, California, Travere Therapeutics was previously known as Retrophin, Inc., adopting its current name in November 2020.
Orphan Technologies
Acquisition in 2020
Orphan Technologies Ltd., based in Rapperswil, Switzerland, specializes in developing innovative therapies for rare disorders, with a primary focus on classical homocystinuria (HCU). Established in 2016, the company's lead candidate, OT-58, is an enzyme replacement therapy specifically optimized to lower homocysteine levels, which are elevated in patients with this genetic condition. HCU is associated with serious complications affecting the cardiovascular, skeletal, neurological, and ophthalmological systems. Orphan Technologies aims to alleviate the burden of this disorder and improve patient outcomes through targeted therapeutic interventions, with potential applications beyond HCU. The company operates as a subsidiary of Travere Therapeutics, Inc.
Manchester Pharmaceuticals
Acquisition in 2014
Manchester Pharmaceuticals is a specialty pharmaceutical company dedicated to developing innovative treatments for patients with ultra-rare diseases. The company focuses on the identification, development, approval, and commercialization of new therapeutic modalities to address the unique needs of this patient population. By concentrating on ultra-rare diseases, Manchester Pharmaceuticals aims to provide effective solutions where options are limited, ultimately improving patient outcomes and enhancing quality of life for those affected by these challenging conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.